RESUMO
Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.
Assuntos
Anticorpos Antivirais/imunologia , Ebolavirus/imunologia , Fosfatidilserinas/imunologia , Vírion/imunologia , Animais , Anticorpos Antivirais/metabolismo , Linhagem Celular , Células Cultivadas , Chlorocebus aethiops , Ebolavirus/metabolismo , Citometria de Fluxo , Imunofluorescência , Doença pelo Vírus Ebola/imunologia , Doença pelo Vírus Ebola/virologia , Humanos , Fosfatidilserinas/metabolismo , Ligação Proteica/imunologia , Células Vero , Vírion/metabolismoRESUMO
Adenovirus late mRNA export is facilitated by viral early proteins of 55 and 34 kDa. The 34-kDa protein contains a leucine-rich nuclear export signal (NES) similar to that of the human immunodeficiency virus Rev protein. It was proposed that the 34-kDa protein might facilitate the export of adenovirus late mRNA through a Rev-like NES-mediated export pathway. We have tested the role of NES-mediated RNA export during adenovirus infection, and we find that it is not essential for the expression of adenovirus late genes.